Of Price And Premiums: Medicare Has Put Alzheimer’s Drug Sponsors On Notice

 
• By Cathy Kelly

Medicare will be closely watching for pricing decisions by Eli Lilly, Eisai and Roche once the companies gain US marketing approval for their amyloid-directed monoclonal antibody drugs for Alzheimer’s disease.

No One Wants The Blame For A Big Premium Increase • Source: Shutterstock

More from Market Access

More from Pink Sheet